Vaccine and Immunization Surveillance in Ontario (VISION) - Using linked health administrative databases to monitor vaccine safety

Vaccine

Volumn 30, Issue 43, 2012, Pages 6115-6120

  Wilson, Kumanan ^a   Hawken, Steven ^a   Kwong, Jeffrey C ^a   Deeks, Shelley L ^a   Crowcroft, Natasha S ^a   Manuel, Douglas ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Health services; Ontario; Pediatric; Self controlled case series; Surveillance; Vaccine safety

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B VACCINE; DIPHTHERIA PERTUSSIS TETANUS POLIOMYELITIS HAEMOPHILUS INFLUENZAE TYPE B VACCINE; MEASLES MUMPS RUBELLA VACCINE; MENINGOCOCCUS VACCINE; PERTUSSIS VACCINE; PNEUMOCOCCUS VACCINE; POLIOMYELITIS VACCINE; UNCLASSIFIED DRUG; VACCINE;

BIRTH WEIGHT; CANADA; CASE STUDY; DATA BASE; DRUG EFFECT; DRUG SURVEILLANCE PROGRAM; EMERGENCY TREATMENT; FEBRILE CONVULSION; GROUPS BY AGE; HEALTH CARE DELIVERY; HEALTH CARE UTILIZATION; HEALTH SERVICE; HOSPITALIZATION; HUMAN; IMMUNIZATION; METHODOLOGY; OUTCOME ASSESSMENT; PREMATURITY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SMALL FOR DATE INFANT; UNSPECIFIED SIDE EFFECT; VACCINATION; VACCINATION REACTION; VIRUS REPLICATION;

ADVERSE DRUG REACTION REPORTING SYSTEMS; CHILD; DATABASES, FACTUAL; HUMANS; INCIDENCE; ONTARIO; POPULATION SURVEILLANCE; VACCINATION; VACCINES;

EID: 84865719298     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.06.004     Document Type: Review

References (28)

1. Chen R.T., Glasser J.W., Rhodes P.H., Davis R.L., Barlow W.E., Thompson R.S., et al. Vaccine Safety Datalink project: a new tool for improving vaccine safety monitoring in the United States. The Vaccine Safety Datalink Team. Pediatrics 1997, 99(6):765-773.
2. Lankinen K.S., Pastila S., Kilpi T., Nohynek H., Makela P.H., Olin P. Vaccinovigilance in Europe - need for timeliness, standardization and resources. Bull World Health Organ 2004, 82(11):828-835.
3. Baggs J., Gee J., Lewis E., Fowler G., Benson P., Lieu T., et al. The Vaccine Safety Datalink: a model for monitoring immunization safety. Pediatrics. 2011, 127(Suppl. 1):S45-S53.
4. Hviid A. Postlicensure epidemiology of childhood vaccination: the Danish experience. Expert Rev Vaccines 2006, 5(5):641-649.
5. Statistics Canada Census of Canada; 2012. (accessed 05.03.12). http://www12.statcan.gc.ca/census-recensement/index-eng.cfm.
6. Whitaker H.J., Farrington C.P., Spiessens B., Musonda P. Tutorial in biostatistics: the self-controlled case series method. Stat Med 2006, 25(10):1768-1797.
7. Farrington P., Pugh S., Colville A., Flower A., Nash J., Morgan-Capner P., et al. A new method for active surveillance of adverse events from diphtheria/tetanus/pertussis and measles/mumps/rubella vaccines. Lancet 1995, 345(8949):567-569.
8. Farrington C.P., Nash J., Miller E. Case series analysis of adverse reactions to vaccines: a comparative evaluation. Am J Epidemiol 1996, 143(11):1165-1173.
9. Guttmann A., Manuel D., Dick P.T., To T., Lam K., Stukel T.A. Volume matters: physician practice characteristics and immunization coverage among young children insured through a universal health plan. Pediatrics 2006, 117(3):595-602.
10. Wilson K., Hawken S., Potter B.K., Chakraborty P., Kwong J., Crowcroft N., et al. Patterns of emergency room visits, admissions and death following recommended pediatric vaccinations - a population based study of 969,519 vaccination events. Vaccine 2011, 29(21):3746-3752.
11. Wilson K., Hawken S., Kwong J.C., Deeks S., Crowcroft N.S., Van Walraven C., et al. Adverse events following 12 and 18 month vaccinations: a population-based, self-controlled case series analysis. PLoS One 2011, 6(12):e27897.
12. Glanz J.M., McClure D.L., Xu S., Hambidge S.J., Lee M., Kolczak M.S., et al. Four different study designs to evaluate vaccine safety were equally validated with contrasting limitations. J Clin Epidemiol 2006, 59(8):808-818.
13. Virtanen M., Peltola H., Paunio M., Heinonen OP Day-to-day reactogenicity and the healthy vaccinee effect of measles-mumps-rubella vaccination. Pediatrics 2000, 106(5):E62.
14. Davis R.L., Marcuse E., Black S., Shinefield H., Givens B., Schwalbe J., et al. MMR2 immunization at 4 to 5 years and 10 to 12 years of age: a comparison of adverse clinical events after immunization in the Vaccine Safety Datalink project. The Vaccine Safety Datalink Team. Pediatrics 1997, 100(5):767-771.
15. Fine P.E., Chen R.T. Confounding in studies of adverse reactions to vaccines. Am J Epidemiol 1992, 136(2):121-135.
16. Barlow W.E., Davis R.L., Glasser J.W., Rhodes P.H., Thompson R.S., Mullooly J.P., et al. The risk of seizures after receipt of whole-cell pertussis or measles, mumps, and rubella vaccine. N Engl J Med 2001, 345(9):656-661.
17. Vestergaard M., Hviid A., Madsen K.M., Wohlfahrt J., Thorsen P., Schendel D., et al. MMR vaccination and febrile seizures: evaluation of susceptible subgroups and long-term prognosis. JAMA 2004, 292(3):351-357.
18. Griffin M.R., Ray W.A., Mortimer E.A., Fenichel G.M., Schaffner W. Risk of seizures after measles-mumps-rubella immunization. Pediatrics 1991, 88(5):881-885.
19. Xu S., Zhang L., Nelson J.C., Zeng C., Mullooly J., McClure D., et al. Identifying optimal risk windows for self-controlled case series studies of vaccine safety. Stat Med 2011, 30(7):742-752.
20. Siegrist CA Mechanisms underlying adverse reactions to vaccines. J Comp Pathol 2007, 137(Suppl. 1):S46-S50.
21. Klein N.P., Fireman B., Yih W.K., Lewis E., Kulldorff M., Ray P., et al. Measles-mumps-rubella-varicella combination vaccine and the risk of febrile seizures. Pediatrics 2010, 126(1):e1-e8.
22. Abdi H. Bonferroni and Šidák corrections for multiple comparisons. Encyclopedia of Measurement and Statistics 2007, Sage, Thousand Oaks, CA. N.J. Salkind (Ed.).
23. Wilson K., Hawken S., Kwong J.C., Deeks S.L., Manuel D.G., Henningsen K.H., et al. Impact of birth weight at term on rates of emergency room visits and hospital admissions following vaccination at 2 months of age. Vaccine 2011, 29(46):8267-8274.
24. Moore G.E., Guptill L.F., Ward M.P., Glickman N.W., Faunt K.K., Lewis H.B., et al. Adverse events diagnosed within three days of vaccine administration in dogs. J Am Vet Med Assoc 2005, 227(7):1102-1108.
25. Wilson K., Hawken S. Incidence of adverse events in premature children following 2 month vaccination. Hum Vaccines Immunother 2012, 8(5):592-595.
26. Hawken S, Manuel DG, Deeks SL, Kwong JC, Crowcroft NS, Wilson K. Underestimating the safety benefits of a new vaccine. The impact of whole-cell versus acellular pertussis vaccine on health services utilization. Am J Epidemiol; in press.
27. Andrews N., Stowe J., Wise L., Miller E. Post-licensure comparison of the safety profile of diphtheria/tetanus/whole cell pertussis/haemophilus influenza type b vaccine and a 5-in-1 diphtheria/tetanus/acellular pertussis/haemophilus influenza type b/polio vaccine in the United Kingdom. Vaccine 2010, 28(44):7215-7220.
28. Scheifele D.W., Halperin S.A. Immunization monitoring program, active: a model of active surveillance of vaccine safety. Semin Pediatr Infect Dis 2003, 14(3):213-219.